Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 5;18(1):20024.
doi: 10.7448/IAS.18.1.20024. eCollection 2015.

Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care

Angela Cescon  1   2 , Sophie Patterson  1   3 , Colin Davey  1   4 , Erin Ding  1 , Janet M Raboud  5   6 , Keith Chan  1 , Mona R Loutfy  6   7 , Curtis Cooper  8 , Ann N Burchell  6   9 , Alexis K Palmer  1   3 , Christos Tsoukas  10 , Nima Machouf  11 , Marina B Klein  10 , Sean B Rourke  6   9 , Anita Rachlis  12 , Robert S Hogg  1   3 , Julio S G Montaner  1   13 ; CANOC Collaboration
Collaborators, Affiliations

Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care

Angela Cescon et al. J Int AIDS Soc. .

Abstract

Introduction: Combination antiretroviral therapy (ART) significantly decreases morbidity, mortality and HIV transmission. We aimed to characterize the timing of ART initiation based on CD4 cell count from 2000 to 2012 and identify factors associated with late initiation of treatment.

Methods: Participants from the Canadian Observational Cohort (CANOC), a multi-site cohort of HIV-positive adults initiating ART naively after 1 January 2000, in three Canadian provinces (British Columbia, Ontario and Québec) were included. Late initiation was defined as a CD4 count <200 cells/mm(3) or an AIDS-defining illness before ART initiation (baseline). Temporal trends were assessed using the Cochran-Armitage test, and independent correlates of late initiation were identified using logistic regression.

Results: In total, 8942 participants (18% female) of median age 40 years (Q1-Q3 33-47) were included. The median baseline CD4 count increased from 190 cells/mm(3) (Q1-Q3 80-320) in 2000 to 360 cells/mm(3) (Q1-Q3 220-490) in 2012 (p<0.001). Overall, 4274 participants (48%) initiated ART with a CD4 count <200 cells/mm(3) or AIDS-defining illness. Late initiation was more common among women, non-MSM, older individuals, participants from Ontario and BC (vs. Québec), persons with injection drug use (IDU) history and individuals starting ART in earlier calendar years. In sub-analysis exploring recent (2008 to 2012) predictors using an updated CD4 criterion (<350 cells/mm(3)), IDU and residence in BC (vs. Québec) were no longer significant correlates of late initiation.

Conclusions: This analysis documents increasing baseline CD4 counts over time among Canadians initiating ART. However, CD4 counts at ART initiation remain below contemporary treatment guidelines, highlighting the need for strategies to improve earlier engagement in HIV care.

Keywords: AIDS; Canada; HIV; HIV care; antiretroviral therapy; late initiation; public health.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution and median of CD4 cell counts at ART initiation in CANOC, 2000–2012 (n=8942). ART, combination antiretroviral therapy; IQR, interquartile range (Q1–Q3).
Figure 2
Figure 2
Median baseline CD4 cell counts at ART initiation by province, 2000–2012 (n=8942). ART, combination antiretroviral therapy; IQR, interquartile range (Q1–Q3); ON, Ontario; QC, Québec; BC, British Columbia.
See this image and copyright information in PMC

References

    1. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568–77. - PubMed
    1. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26. - PMC - PubMed
    1. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ. 2011;343:d6016. - PMC - PubMed
    1. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133–44. - PubMed
    1. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–20. - PMC - PubMed

Publication types

Substances